The natriuretic peptide family consists of three endogenous ligands: atrial natriuretic peptide (ANP), brain natriuretic peptide (BNP), and C-type natriuretic peptide (CNP). They exert their biological actions through two subtypes of particulate guanylyl cyclase (GC): GC-A for ANP and BNP, and GC-B for CNP. Among the natriuretic peptide family members, ANP and BNP are cardiac hormones that are produced and released from the atrium and ventricle of the heart, respectively, and play important roles in the regulation of the cardiovascular system. On the other hand, although CNP and its receptor, GC-B, exist ubiquitously in the body, we elucidated that the CNP/GC-B system is a crucial stimulator of endochondral bone growth, using CNP or GC-B knockout or transgenic mice. We planned to utilize the activation of the CNP/GC-B pathway as a novel therapeutic strategy for skeletal dysplasia, which consists of multiple skeletal diseases including those with impaired bone growth. We tried to investigate this effect on impaired skeletal growth in a mouse model of achondroplasia, the most common form of skeletal dysplasias, and successfully recovered the skeletal phenotype by using transgenic technology or by administration of synthetic CNP. In the future, the activation of the CNP/ GC-B system may constitute a novel therapeutic strategy for the treatment of skeletal dysplasias.
Introduction
The natriuretic peptide family consists of three endogenous ligands: atrial natriuretic peptide (ANP), brain natriuretic peptide (BNP), and C-type natriuretic peptide (CNP) [ 1 ] . They exert their biological actions through two subtypes of particulate guanylyl cyclase (GC): GC-A for ANP and BNP, and GC-B for CNP [ 2 ] . Among the natriuretic peptide family members, ANP and BNP are cardiac hormones that are produced and released from the atrium and ventricle of the heart, respectively, and play important roles in the regulation of the cardiovascular system [ 3 -7 ] . CNP, a third member of the natriuretic peptide family, was fi rst purifi ed from porcine brain [ 8 ] . Therefore, CNP was thought to be the primary natriuretic peptide in the brain, but has been proved to exist ubiquitously in the body, e.g., in the blood vessels, gonads, adrenal gland, etc. [ 9 -15 ] (Fig. 1 ) . Furthermore, analysis of the CNP/GC-B system in genetically engineered mice revealed that CNP and GC-B play a pivotal role in the regulation of endochondral bone growth. The CNP/GC-B System 
Skeletal Phenotypes of the CNP/GC-B System in Genetically Engineered Mice
Targeted disruption of the CNP gene ( Nppc ) causes prominent short stature due to impaired bone growth in mice [ 16 ] (Fig. 2 ) . Mammalian bones are formed through two different mechanisms, endochondral ossifi cation and membranous ossifi cation. Most mammalian bones are formed through endochondral ossifi cation, in which the growth of bone is dependent on the growth of cartilaginous anlage as the scaffold of bone; later, it is replaced by calcifi ed bone [ 17 ] . In the process of endochondral ossifi cation, chondrocytes in the growth plate undergo proliferation, hypertrophy, and cell death, and fi nally are replaced by osteoblasts. The short-stature phenotype of CNP knockout (CNP-KO) mice results from impaired bone growth through endochondral ossifi cation. Histological analysis of the growth plate of CNP-KO mice revealed that every chondrocyte layer of the growth plate is narrower in CNP-KO mice than in wild-type mice. Furthermore, mice depleted with the GC-B gene ( Npr2 ) exhibit the same short-stature phenotype observed in CNP-KO mice, demonstrating that the CNP/GC-B system is a physiologically important stimulator of endochondral bone growth [ 18 ] . In contrast, cartilage-specifi c CNP transgenic mice under the control of type II collagen promoter (col2-CNP-Tg mice) exhibit prominent overgrowth of bones formed through endochondral ossifi cation [ 19 ] (Fig. 3a ) . In contrast to CNP-or GC-B-KO mice, every chondrocyte layer, especially hypertrophic chondrocyte layer, of the growth plate of col2-CNP-Tg mice is wider than that of wild-type mice (Fig. 3b ) . Collectively, the CNP/GC-B system is a physiological stimulator of endochondral bone growth and can potently stimulate bone growth as a local regulator.
Importance of CNP/GC-B Signaling in Endochondral Bone Growth in Humans: Lessons from Rare Congenital Skeletal Disorders
Skeletal dysplasias are human genetic disorders of the skeleton, whose feature is impairment of bones. In 2004, Bartels et al., reported that acromesomelic dysplasia, type Maroteaux, one form of skeletal dysplasia with a severely impaired bone growth phenotype, is caused by a loss-of-function mutation in the human GC-B gene [ 20 ] . In fact, the skeletal phenotype observed in this disorder was just the same as that of GC-B-KO mice, and here for the fi rst time, the CNP/GC-B signaling was proved to be a physiological and potent stimulator of endochondral bone growth not only in mice but also in humans. Later, in 2012, Miura et al., reported a Japanese case of skeletal overgrowth phenotype and showed that it was caused by a constitutively activated mutation in the GC-B gene [ 21 ] . They also reported a Korean case of skeletal overgrowth caused by a constitutive active mutation in the GC-B gene [ 22 ] . Thus, the notion that the CNP/GC-B system is a potent stimulator of endochondral bone in human is fi rmly established so far.
Translational Research into Activation of CNP/GC-B Signaling for Skeletal Dysplasias
Following these results, we planned to start translational research into activation of the CNP/GC-B system for disorders with impaired bone growth in skeletal dysplasias. Achondroplasia is the most common form of skeletal dysplasias, with a birth prevalence of ~1:10,000. Patients suffering from achondroplasia exhibit short stature (fi nal height: ~130 cm in males and ~120 cm in females) and a short-limbed dwarf phenotype owing to impaired endochondral bone growth, and it had been shown to be caused by a constitutive active mutation in the FGF receptor 3 (FGFR3) gene, followed by a decrease in the proliferation of chondrocytes in the growth plate [ 23 , 24 ] . Current therapies for achondroplasia consist of distraction osteogenesis, an orthopedic procedure, and administration of growth hormone [ 25 ] . Although distraction osteogenesis gives better results, it lays a burden on patients and limits their quality of life. Growth hormone has a minimal effect. Therefore, we started translational research into activation of the CNP/GC-B system for this disease. We obtained transgenic mice with targeted overexpression of activated FGFR3 (G380R mutation in humans) in cartilage, using type II collagen promoter as a mouse model of achondroplasia (Ach mice) [ 26 ] . As shown in Fig. 4 , Ach mice show short stature and an impaired bone growth phenotype, and mimic the skeletal phenotype of achondroplastic patients. We achieved targeted overexpression of CNP in the growth plate of Ach mice by crossing them with col2-CNP-Tg mice. The short stature observed in Ach mice, owing to their impaired bone growth, was recovered in the double transgenic Ach/col2-CNP-Tg mice and grew almost comparable to that of wild-type mice (Fig. 4 ) . As was previously reported, the length of the Ach mice was significantly shorter at least at the third week after birth, and more than 10 % shorter after 6 weeks of age, than that of their wild-type litter mates. In Ach/col2-CNP-Tg mice, the decrease in the length of Ach mice was recovered, and the length became comparable to that of their wild-type litter mates. A soft x-ray picture revealed that the shortening of Ach bones was almost completely recovered in double transgenic bones. But the width of the cranium, which is made through membranous ossifi cation, was not changed. Histological examination of the tibial growth plate showed that the width of the growth plate of Ach mice was shorter than that of wildtype mice, but was restored in the growth plate of the double transgenic mice [ 19 ] .
Next, in order to test the effect of elevated plasma concentrations of CNP on endochondral bone growth, we generated transgenic mice with an elevated plasma concentration of CNP, using human serum amyloid P component promoter, which enables targeted overexpression of CNP in the liver (SAP-CNP-Tg mice) (Fig. 5 ) . The resultant SAP-CNP-Tg mice, which have about two times the plasma CNP concentration of wild-type mice, exhibited skeletal overgrowth just like col2-CNPTg mice [ 27 ] . Then we mated Ach mice with the SAP-CNP-Tg mice and tried to rescue the impaired endochondral bone growth of Ach mice by increased circulating CNP. We could successfully rescue the short-stature phenotype of Ach mice in the double transgenic Ach/SAP-CNP-Tg mice (Fig. 6a ) . After 6 weeks of age, the short stature observed in Ach mice was completely rescued in Ach/SAP-CNP-Tg mice. Skeletal analysis by a soft x-ray picture also exhibited that the impaired bone growth of Ach mice was rescued by increased circulating CNP (Fig. 6b ) . The lengths of the humerus, radius, ulna, femur, and tibia of the double transgenic mice were rather longer than those of wild-type mice. Histological examination revealed that the shortened growth plate of Ach mice was rescued in Ach/SAP-CNP-Tg mice and became rather elongated in comparison with the wild-type mice [ 28 ] .
Finally, we tried to administrate CNP to Ach mice. Ach mice were about 10 % shorter than wild-type mice at the beginning of administration at the age of 3 weeks. Administration of CNP at the dose of 1 μg/kg/min stimulated the growth of Ach mice, and their length was almost comparable to that of wild-type mice at the end of the 4-week administration period (Fig. 7a ) . A soft x-ray picture revealed that the impaired skeletal growth observed in Ach mice was recovered by administration of CNP. Administration of 0.1 μg/kg/min of CNP considerably rescued the shortness of Ach bones, and 1 μg/kg/min elongated them to an extent rather longer than those of vehicle-treated wild-type mice. Histological examination revealed that the narrowed growth plate of Ach mice was recovered and became comparable to that of wildtype mice through administration of CNP at the dose of 1 μg/kg/min (Fig. 7b ) [ 28 ] .
Conclusions and Future Prospects
We have elucidated that CNP/GC-B signaling is a physiological stimulator of endochondral bone growth and exhibited that the activation of this pathway strongly stimulates longitudinal bone growth in mice model. Furthermore, clinical reports showed that decreased signaling of this pathway causes impaired endochondral bone growth (acromesomelic dysplasia, type Maroteaux), and increased signaling causes skeletal overgrowth phenotype in humans. We started translational research into CNP/GC-B therapy for skeletal dysplasias using a mouse model of achondroplasia, and successfully rescued their impaired skeletal growth phenotype. Nevertheless, there remain several problems to be solved to make CNP/GC-B therapy a reality for skeletal dysplasias. In the preclinical study described here, we had to administrate CNP intravenously, not subcutaneously, because CNP is easily degraded by subcutaneous endopeptidase. First, therefore, in the event that we use CNP, we must develop a way of administering CNP. Second, in relevance to this point, modifi cation of the clearance system of CNP may be another approach for activating the CNP/GC-B system [ 29 ] .
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